MAP2K7 and melanoma: We set out to clarify the type, incidence, and Risk ratio of CAEs in patients with melanoma who are being treated with combined BRAF and MEK inhibitors therapy compared with patients receiving BRAF inhibitor alone in this systematic review and meta-analysis.